Cited by 211Angiogenesis and VEGF in CancerDermatology and Skin DiseasesLymphatic System and Diseases

Angiogenesis in Chronic Inflammatory Skin Disorders

Open access
Lee, Hyun Ji, Hong, Yong Jun, Kim, Miri·2021·International Journal of Molecular Sciences

Abstract

Angiogenesis, the growth of new blood vessels from preexisting vessels, is associated with inflammation in various pathological conditions. Well-known angiogenetic factors include vascular endothelial growth factor (VEGF), angiopoietins, platelet-derived growth factor, transforming growth factor-β, and basic fibroblast growth factor. Yes-associated protein 1 (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) have recently been added to an important angiogenic factor. Accumulating evidence indicates associations between angiogenesis and chronic inflammatory skin diseases. Angiogenesis is deeply involved in the pathogenesis of psoriasis. VEGF, angiopoietins, tumor necrosis factor-a, interleukin-8, and interleukin-17 are unregulated in psoriasis and induce angiogenesis. Angiogenesis may be involved in the pathogenesis of atopic dermatitis, and in particular, mast cells are a major source of VEGF expression. Angiogenesis is an essential process in rosacea, which is induced by LL-37 from a signal cascade by microorganisms, VEGF, and MMP-3 from mast cells. In addition, angiogenesis by increased VEGF has been reported in chronic urticaria and hidradenitis suppurativa. The finding that VEGF is expressed in inflammatory skin lesions indicates that inhibition of angiogenesis is a useful strategy for treatment of chronic, inflammatory skin disorders.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms222112035

Cites

121 of 121 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increasing real-world evidence supports the durable efficacy and favorable long-term disease control achieved with selective IL-23 inhibitors.

    “Increasing real-world evidence also supports the durable efficacy and favorable long-term disease control achieved with selective IL-23 inhibitors [27,28].”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [28]

    The Psoriasis section says anti-IL-23 treatments have proved more effective with fewer adverse events. It does not report real-world evidence or establish durable efficacy and long-term disease control for selective IL-23 inhibitors. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Throughout the psoriatic process, continuous exchange between keratinocytes and immune cells maintains a loop in which IL-23 sustains pathogenic T cells, IL-17 and IL-22 perpetuate epidermal alterations, and TNF-α amplifies inflammation across multiple cell types.

    “Throughout this process, continuous exchange between keratinocytes and immune cells maintains a loop in which IL-23 sustains pathogenic T cells, IL-17 and IL-22 perpetuate epidermal alterations, and TNF-α amplifies inflammation across multiple cell types.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [28]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Psoriasis histopathological findings reflect activation of the IL-23/Th17 axis.

    “These reflect activation of the IL-23/Th17 axis.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [28]

    The Psoriasis section (page not available) describes vascular changes in psoriatic lesions and says IL-17 from Th17 cells promotes angiogenesis. It also mentions effective anti-IL-23 treatments, but does not state that the histopathological findings reflect activation of an IL-23/Th17 axis. (LLM, conf=0.82)

    Experimental — accuracy not yet measured
  • In psoriasis, histopathological findings include acanthosis, parakeratosis, neutrophilic microabscesses, and prominent dermal vascular proliferation.

    “In psoriasis, histopathological findings include acanthosis, parakeratosis, neutrophilic microabscesses, and prominent dermal vascular proliferation.”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [28]

    Section 3 (Psoriasis; page not provided) describes epidermal hyperplasia and microvascular proliferation in psoriatic lesions, supporting the epidermal-thickening and vascular parts of the claim. It does not describe parakeratosis or neutrophilic microabscesses as histopathological findings; its mention of neutrophils concerns cytokine secretion. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • In severe or refractory psoriasis, systemic agents such as methotrexate, cyclosporine, and acitretin broadly suppress immune activation and keratinocyte turnover, but their long-term use is limited by toxicity and lack of pathway specificity.

    “In severe or refractory cases, systemic agents such as methotrexate, cyclosporine, and acitretin are used to broadly suppress immune activation and keratinocyte turnover, but their long-term use is limited by toxicity and lack of pathway specificity [28].”

    From The Cutaneous Immune Microenvironment in Selected Inflammatory Skin Diseases: Linking Histopathology, Mechanisms, and Targeted Therapy (2026) · cites this paper as [28]

    Split into 2 atoms — 0 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 2 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 123 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Lee, H. J., Hong, Y. J., & Kim, M.
Affiliations
The Catholic University of Korea Yeouido St. Mary's Hospital (KR)
Corresponding author
Kim, Miri
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2021-11-07
Volume
22
Issue
21
Pages
12035
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3212070111
Cited by
211
References
123
Citations by year
2026: 31 · 2025: 63 · 2024: 55 · 2023: 43 · 2022: 19
FWCI
3.07
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Research Foundation of Korea (2018R1D1A1B07044100 and 2019R1F1A1059460)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
Keywords
angiogenesis, chronic inflammatory skin disease, psoriasis, atopic dermatitis, rosacea, chronic urticaria, hidradenitis suppurativa, vascular endothelial growth factor, angiopoietins, mast cells, YAP/TAZ signaling, angiogenesis inhibition, IL-17, interleukin-8, TNF-α, LL-37, MMP-3
MeSH terms
Animals, Chronic Disease, Dermatitis, Dermatitis, Atopic, Humans, Neovascularization, Pathologic, Psoriasis, Rosacea, Vascular Endothelial Growth Factor A, Angiopoietins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review